Transfer factor and hepatitis B: a double blind study.
A prospective, double blind placebo-controlled trial was carried out on twenty-nine patients with hepatitis B. Thirteen received transfer factor and sixteen placebo. There were no significant differences between the two groups in any clinical or laboratory measurements made, although a rapid early reduction of serum aspartate transaminase levels by transfer factor is possible. Similarly, no significant changes were delineated by the in vitro measurements of lymphocyte function. Transfer factor did not alter the natural course of hepatitis B.
D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D010919:Placebos; D014165:Transfer Factor / Q000627:therapeutic use*
D010919:Placebos; D014165:Transfer Factor; D001219:Aspartate Aminotransferases; D001663:Bilirubin